The Combination of IMGN632, a CD123-Targeting ADC, with Venetoclax Enhances Anti-Leukemic Activity In vitro and Prolongs Survival In vivo in Pre-Clinical Models of Human AML
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.